202 related articles for article (PubMed ID: 10720055)
1. Angiogenesis in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Mar; 85(3):1159-62. PubMed ID: 10720055
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
J Endocrinol; 2000 May; 165(2):475-81. PubMed ID: 10810311
[TBL] [Abstract][Full Text] [Related]
3. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Wass JA; Harris AL
Br J Cancer; 2000 Apr; 82(8):1441-5. PubMed ID: 10780524
[TBL] [Abstract][Full Text] [Related]
4. Role of matrix metalloproteinase 9 in pituitary tumor behavior.
Turner HE; Nagy Z; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Aug; 85(8):2931-5. PubMed ID: 10946906
[TBL] [Abstract][Full Text] [Related]
5. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas.
Viacava P; Gasperi M; Acerbi G; Manetti L; Cecconi E; Bonadio AG; Naccarato AG; Acerbi F; Parenti G; Lupi I; Genovesi M; Martino E
J Endocrinol Invest; 2003 Jan; 26(1):23-8. PubMed ID: 12602530
[TBL] [Abstract][Full Text] [Related]
6. Microvessel density in pituitary adenomas and carcinomas.
Vidal S; Kovacs K; Horvath E; Scheithauer BW; Kuroki T; Lloyd RV
Virchows Arch; 2001 Jun; 438(6):595-602. PubMed ID: 11469692
[TBL] [Abstract][Full Text] [Related]
7. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in pituitary adenomas.
Yamada S; Takada K
Microsc Res Tech; 2003 Feb; 60(2):236-43. PubMed ID: 12539178
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between tumor blood vessels heterogeneity and hormonal profile of pituitary adenomas: evidence and controversies.
Bălinişteanu B; Cimpean AM; Melnic E; Coculescu M; Ceauşu RA; Raica M
Anticancer Res; 2014 Oct; 34(10):5413-20. PubMed ID: 25275036
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and pituitary tumors.
Cohen AB; Lessell S
Semin Ophthalmol; 2009; 24(3):185-9. PubMed ID: 19437356
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Sullivan N; Esiri MM; Wass JA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):337-44. PubMed ID: 10971451
[TBL] [Abstract][Full Text] [Related]
14. Altered balance between thyrotropin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries.
Le Dafniet M; Blumberg-Tick J; Gozlan H; Barret A; Joubert Bression D; Peillon F
J Clin Endocrinol Metab; 1989 Aug; 69(2):267-71. PubMed ID: 2502552
[TBL] [Abstract][Full Text] [Related]
15. Microvessel density and area in pituitary microadenomas.
Jasek E; Furgal-Borzych A; Lis GJ; Litwin JA; Rzepecka-Wozniak E; Trela F
Endocr Pathol; 2009; 20(4):221-6. PubMed ID: 19705298
[TBL] [Abstract][Full Text] [Related]
16. Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas.
Takada K; Yamada S; Teramoto A
Endocr Pathol; 2004; 15(2):131-9. PubMed ID: 15299199
[TBL] [Abstract][Full Text] [Related]
17. Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes.
Rotondo F; Sharma S; Scheithauer BW; Horvath E; Syro LV; Cusimano M; Nassiri F; Yousef GM; Kovacs K
Neoplasma; 2010; 57(6):590-3. PubMed ID: 20845998
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
20. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
